IDEAYA Biosciences, Inc.
IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methyltā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.12
Price-0.04%
-$0.01
1Y
Price
Market Cap
$2.471b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1637.2%
EBITDA Margin-1502.1%
Net Profit Margin-1160.6%
Free Cash Flow Margin-1637.2%
EBITDA Margin-1502.1%
Net Profit Margin-1160.6%
Free Cash Flow MarginRevenue
$225.270m
+3.0%
1y CAGR+985.8%
3y CAGR+725.8%
5y CAGREarnings
-$140.059m
-23.2%
1y CAGR-35.9%
3y CAGR-50.0%
5y CAGREPS
-$1.60
-25.0%
1y CAGR-11.5%
3y CAGR-18.1%
5y CAGRBook Value
$937.267m
$1.030b
Assets$93.081m
Liabilities$28.600m
DebtDebt to Assets
2.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$87.931m
-19.7%
1y CAGR-20.9%
3y CAGR-23.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company